The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Estrogen plus Progestin and Colorectal Cancer in Postmenopausal Women
Abstract
BACKGROUND: Although the Women's Health Initiative (WHI) trial of estrogen plus progestin in postmenopausal women identified more overall health risks than benefits among women in the hormone group, the use of estrogen plus progestin was associated with a significant decrease in the risk of colorectal cancer. We analyzed features of the colorectal cancers that developed and their relation to the characteristics of the participants. METHODS: In the WHI trial, 16,608 postmenopausal women who were 50 to 79 years of age and had an intact uterus were randomly assigned to a combination of conjugated equine estrogens (0.625 mg per day) plus medroxyprogesterone acetate (2.5 mg per day) or placebo. The main outcome measures were the incidence, stages, and types of colorectal cancer, as determined by blinded central adjudication. RESULTS: There were 43 invasive colorectal cancers in the hormone group and 72 in the placebo group (hazard ratio, 0.56; 95 percent confidence interval, 0.38 to 0.81; P=0.003). The invasive colorectal cancers in the hormone group were similar in histologic features and grade to those in the placebo group but with a greater number of positive lymph nodes (mean +/-SD, 3.2+/-4.1 vs. 0.8+/-1.7; P=0.002) and were more advanced (regional or metastatic disease, 76.2 percent vs. 48.5 percent; P=0.004). In exploratory analyses, women in the hormone group with antecedent vaginal bleeding had colorectal cancers with a greater number of positive nodes than women in the hormone group who did not have vaginal bleeding (3.8+/-4.3 vs. 0.7+/-1.5 nodes, P=0.006). CONCLUSIONS: Relatively short-term use of estrogen plus progestin was associated with a decreased risk of colorectal cancer. However, colorectal cancers in women who took estrogen plus progestin were diagnosed at a more advanced stage than those in women who took placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.5 · Cited by 3,275
Design of the Women’s Health Initiative Clinical Trial and Observational Study
(1998) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)00078-0 · Cited by 2,585
Fundamentals of Clinical Chemistry.
(1977) · Annals of Internal Medicine · doi:10.7326/0003-4819-87-1-142_1 · Cited by 2,561
The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
Steinbach, G., Lynch, P. M., Phillips, R. K. S., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006293422603 · Cited by 2,526
Shumaker, S. A., Legault, C., Rapp, S. R., Thal, L., Wallace, R. B., Ockene, J. K., Hendrix, S. L., Jones III, B. N., Assaf, A. R., Jackson, R. D., et al. (2003) · JAMA · doi:10.1001/jama.289.20.2651 · Cited by 2,178
Self-citationWINAWER, S. (2003) · Gastroenterology · doi:10.1053/gast.2003.50044 · Cited by 2,143
Grady, D., Herrington, D., Bittner, V., Blumenthal, R., Davidson, M., Hlatky, M., Hsia, J., Hulley, S., Herd, A., Khan, S., et al. (2002) · JAMA · doi:10.1001/jama.288.1.49 · Cited by 1,930
Chlebowski, R. T., Hendrix, S. L., Langer, R. D., Stefanick, M. L., Gass, M., Lane, D., Rodabough, R. J., Gilligan, M. A., Cyr, M. G., Thomson, C. A., et al. (2003) · JAMA · doi:10.1001/jama.289.24.3243 · Cited by 1,872
Self-citationTreatment of Colonic and Rectal Adenomas with Sulindac in Familial Adenomatous Polyposis
Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hylind, L. M., Celano, P., Booker, S. V., Robinson, C. R., & Offerhaus, G. J. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305063281805 · Cited by 1,717
American Cancer Society Guidelines for the Early Detection of Cancer
Smith, R. A., Cokkinides, V., von Eschenbach, A. C., Levin, B., Cohen, C., Runowicz, C. D., Sener, S., Saslow, D., & Eyre, H. J. (2002) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.52.1.8 · Cited by 1,588
Sandler, R. S., Halabi, S., Baron, J. A., Budinger, S., Paskett, E., Keresztes, R., Petrelli, N., Pipas, J. M., Karp, D. D., Loprinzi, C. L., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021633 · Cited by 1,136
Ma, J., Pollak, M. N., Giovannucci, E., Chan, J. M., Tao, Y., Hennekens, C. H., & Stampfer, M. J. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.7.620 · Cited by 1,119
Calcium Supplements for the Prevention of Colorectal Adenomas
Baron, J. A., Beach, M., Mandel, J. S., van Stolk, R. U., Haile, R. W., Sandler, R. S., Rothstein, R., Summers, R. W., Snover, D. C., Beck, G. J., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400204 · Cited by 865
The women's health initiative recruitment methods and results
Hays, J., Hunt, J. R., Hubbell, F. A., Anderson, G. L., Limacher, M., Allen, C., & Rossouw, J. E. (2003) · Annals of Epidemiology · doi:10.1016/s1047-2797(03)00042-5 · Cited by 742
Self-citationSulindac causes regression of rectal polyps in familial adenomatous polyposis
Labayle, D., Fischer, D., Vielh, P., Drouhin, F., Pariente, A., Bories, C., Duhamel, O., Trousset, M., & Attali, P. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90519-q · Cited by 719
Kanaya, A. M., Herrington, D., Vittinghoff, E., Lin, F., Grady, D., Bittner, V., Cauley, J. A., & Barrett-Connor, E. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-1-200301070-00005 · Cited by 633
Hulley, S., Furberg, C., Barrett-Connor, E., Cauley, J., Grady, D., Haskell, W., Knopp, R., Lowery, M., Satterfield, S., Schrott, H., et al. (2002) · JAMA · doi:10.1001/jama.288.1.58 · Cited by 595
Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis
Grodstein, F., Newcomb, P. A., & Stampfer, M. J. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00063-7 · Cited by 584
Pardi, D. S., Loftus, E. V., Kremers, W. K., Keach, J., & Lindor, K. D. (2003) · Gastroenterology · doi:10.1053/gast.2003.50156 · Cited by 562
American Cancer Society Guidelines for the Early Detection of Cancer, 2003
Smith, R. A., Cokkinides, V., & Eyre, H. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.27 · Cited by 529
Chemoprevention of Colorectal Cancer
Jänne, P. A., & Mayer, R. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006293422606 · Cited by 496
Calle, E. E., Miracle-McMahill, H. L., Thun, M. J., & Heath, C. W. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.7.517 · Cited by 360
Hulley, S., Furberg, C., & Barrett-Connor, E. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00920-0 · Cited by 339
Reproduction, Endogenous and Exogenous Sex Hormones, and Colon Cancer: A Review and Hypothesis
(1980) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/65.6.1201 · Cited by 336
How does colorectal cancer present? symptoms, duration, and clues to location
Majumdar, S. (1999) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(99)00510-9 · Cited by 278
Postmenopausal Hormone Use and Risk of Large-Bowel Cancer
Newcomb, P. A., & Storer, B. E. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.14.1067 · Cited by 230
Association of markers of insulin and glucose control with subsequent colorectal cancer risk.
Saydah, S., Platz, E. A., Rifai, N., Pollak, M., Brancati, F. L., & Helzlsouer, K. J. (2003) · PubMed · Cited by 177
The presence of functional estrogen receptors in intestinal epithelial cells
Thomas, M. L., Xu, X., Norfleet, A. M., & Watson, C. S. (1993) · Endocrinology · doi:10.1210/endo.132.1.8419141 · Cited by 146
Chang, C., & Ulrich, C. M. (2003) · Diabetologia · doi:10.1007/s00125-003-1109-5 · Cited by 115
Pre-diagnostic symptom recognition and help seeking among cancer patients
Mor, V., Masterson‐Allen, S., Goldberg, R., Guadagnoli, E., & Wool, M. S. (1990) · Journal of Community Health · doi:10.1007/bf01350291 · Cited by 115
Pyruvate inhibits zinc-mediated pancreatic islet cell death and diabetes
Chang, I., Cho, N., Koh, J., & Lee, M. (2003) · Diabetologia · doi:10.1007/s00125-003-1171-z · Cited by 104
Hormone replacement therapy and risk of colon and rectal cancer.
Fernández, E., Vecchia, C. L., Braga, C., Talamini, R., Negri, E., Parazzini, F., & Franceschi, S. (1998) · PubMed · Cited by 92
Estrogen receptor β is expressed in human colorectal adenocarcinoma
Witte, D. A., Chirala, M., Younes, A., Li, Y., & Younes, M. (2001) · Human Pathology · doi:10.1053/hupa.2001.27117 · Cited by 78
Estrogen replacement therapy: determinants of persistence with treatment
Pilon, D., Castilloux, A. M., & LeLorier, J. (2001) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(00)01104-2 · Cited by 56
Estrogen replacement therapy and colorectal cancer risk in elderly women
Paganini‐Hill, A. (1999) · Diseases of the Colon & Rectum · doi:10.1007/bf02234219 · Cited by 52
Gender and Illness Behavior Among Colorectal Cancer Patients
Marshall, J. R. (1987) · Women & Health · doi:10.1300/j013v11n03_06 · Cited by 44
Bone Mass and the Risk of Colon Cancer among Postmenopausal Women
Zhang, Y., Felson, D. T., Ellison, R. C., Kreger, B. E., Schatzkin, A. G., Dorgan, J. F., Cupples, L. A., Levy, D. A., & Kiel, D. P. (2001) · American Journal of Epidemiology · doi:10.1093/aje/153.1.31 · Cited by 27
O'Donnell, S., & Tuomey, J. (2004) · Arrow@dit (Dublin Institute of Technology) · Cited by 8
Cited by
Manson, J. E., Chlebowski, R. T., Stefanick, M. L., Aragaki, A. K., Rossouw, J. E., Prentice, R. L., Anderson, G., Howard, B. V., Thomson, C. A., LaCroix, A. Z., et al. (2013) · JAMA · doi:10.1001/jama.2013.278040 · Cited by 1,650
Self-citationBreast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Obesity and cancer risk: Emerging biological mechanisms and perspectives
Avgerinos, K. I., Spyrou, N., Mantzoros, C. S., & Dalamaga, M. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.001 · Cited by 1,567
Jemal, A., Clegg, L. X., Ward, E., Ries, L. A. G., Wu, X., Jamison, P. M., Wingo, P. A., Howe, H. L., Anderson, R. N., & Edwards, B. K. (2004) · Cancer · doi:10.1002/cncr.20288 · Cited by 1,140
The 2022 hormone therapy position statement of The North American Menopause Society
(2022) · Menopause · doi:10.1097/gme.0000000000002028 · Cited by 977
Metadata
- Authors
- Chlebowski, R. T., Wactawski-Wende, J., Ritenbaugh, C., Hubbell, F. A., Ascensao, J., Rodabough, R. J., Rosenberg, C. A., Taylor, V. M., Harris, R., Chen, C., Adams-Campbell, L. L., & White, E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-03-04
- Volume
- 350
- Issue
- 10
- Pages
- 991-1004
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2164414963
- Cited by
- 669
- References
- 39
- FWCI
- 25.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.